Biotech blitz: Moderna, Bluebird lead $3 bln capital raise wave

Bellerophon Therapeutics

19/05/2020 13:25

** Moderna Inc  MRNA.O  and bluebird bio inc  BLUE.O  lead
biotech deal blitz as 8 cos price offerings totaling nearly $3
bln
    ** MRNA represents about half the haul with its upsized
$1.34 bln follow-on  urn:newsml:reuters.com:*:nL1N2D10FT, while BLUE sells ~9.1 mln
shares at $55, ~4% discount to its stock's Mon close, for a $500
mln gross raise  urn:newsml:reuters.com:*:nBw3x126Ba  urn:newsml:reuters.com:*:nL1N2D00IT
    ** Oncology co Turning Point Therapeutics  TPTX.O , which
IPOd in Apr 2019 at $18/sh, prices $325 mln stock offering at
$60  urn:newsml:reuters.com:*:nGNX3BsWxS, and Gossamer Bio  GOSS.O  also raises $325 mln
through stock offering and concurrent $200 mln 7-yr convertible
bond deal  urn:newsml:reuters.com:*:nBw2c8Lwta
    ** Gene therapy firm Krystal Biotech  KRYS.O  offers 2.3 mln
shares at $55 for $125 mln raise  urn:newsml:reuters.com:*:nGNX7vBngQ
    ** Clovis Oncology  CLVS.O  raises ~$89 mln in follow-on
priced at $8.05, ~10% discount to stock's last sale
 urn:newsml:reuters.com:*:nBw2QbQGSa. Equity raise comes on heels of U.S. FDA approval
on Fri of its prostate cancer drug Rubraca  urn:newsml:reuters.com:*:nL4N2D02T4
 urn:newsml:reuters.com:*:nL4N2CX3ZK
    ** Smaller equity raises come from Israeli biotech Gamida
Cell  GMDA.O  ($60 mln) in offering priced at $4.50 (~24%
discount to last sale)  urn:newsml:reuters.com:*:nBw805mgwa and Bellerophon Therapeutics
Inc  BLPH.O  ($40 mln) in deal priced at $13 (~20% discount to
Mon close)  urn:newsml:reuters.com:*:nGNXcc8ClX

 (Lance Tupper is a Reuters market analyst. The views expressed
are his own)
 ((lance.tupper.tr.com@reuters.net
lance.tupper@tr.com 646-223-5017))